Table 4.
Group |
Β2-MG (mg/L)
|
VILIP-1 (ng/L)
|
GFAP (mg/L)
|
|||
Before treatment
|
After treatment
|
Before treatment
|
After treatment
|
Before treatment
|
After treatment
|
|
Study group (n = 30) | 2.64 ± 0.65 | 1.49 ± 0.48a | 520.59 ± 55.39 | 409.67 ± 40.77a | 9.17 ± 1.32 | 6.04 ± 1.70a |
Control group (n = 30) | 2.79 ± 0.42 | 1.93 ± 0.28a | 531.47 ± 54.03 | 435.83 ± 37.09a | 9.87 ± 1.56 | 7.44 ± 1.06a |
P value | 0.294 | < 0.001 | 0.444 | 0.012 | 0.064 | < 0.001 |
t value | 1.061 | 4.339 | 0.771 | 2.599 | 1.888 | 3.817 |
P < 0.05 compared to the same group before treatment.
β2-MG: β2-microglobulin; GFAP: Glial fibrillary acidic protein; VILIP-1: Visinin-like protein 1.